|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,683,235: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 4,683,235?
U.S. Patent 4,683,235 was granted on August 4, 1987, to Novo Nordisk for pharmaceutical compositions containing insulin. The patent claims cover specific formulations of insulin, primarily focused on stable, long-acting insulin preparations. It targets a subset of insulin analogs and formulations designed for extended duration of action.
Patent Scope Summary:
- Main subject: Long-acting insulin formulations
- Delivery: Subcutaneous injection
- Composition details:
- Aqueous solutions containing insulin
- Use of zinc (Zn²⁺), protamine, or similar agents to prolong insulin action
- Specific pH ranges (typically around 7.0)
- Stabilization agents to maintain insulin activity over time
- Purpose: To provide a stable, slow-release insulin suitable for once-daily injections
Limitations:
- The patent does not cover injectable insulin analogs with altered amino acid sequences.
- The claims do not extend to non-parenteral routes or oral insulin delivery methods.
- Formulations with different stabilizers and additives outside the described scope are not included.
What are the key claims?
The patent contains 13 claims, primarily focused on the formulation aspects:
Principal Claims:
- Claim 1: An aqueous insulin composition comprising insulin and zinc ions, with the pH maintained around 7, and characterized by its long-acting nature due to the zinc-insulin complex formation, providing a stable, slow-release profile.
- Claim 2: The composition where protamine is included to further prolong activity.
- Claims 3-6: Variations with specific concentrations of zinc, insulin, and stabilizers, and adjusted pH levels for optimized stability.
Narrower Claims:
- Include specific ratios of insulin to zinc.
- Formulations further containing buffers or stabilizers.
- Specific formulations with particular pH ranges (about 6.5–7.5).
Exclusions:
- No claims covering recombinant DNA methods or non-insulin peptides.
- No scope for novel insulin analogs with modified amino acid sequences.
How does the patent landscape look for insulin formulations?
Patent family components:
- The patent was part of a series of filings related to insulin stabilization and long-acting analogs.
- It built upon prior therapeutic insulin patents, notably U.S. Patent 4,543,434 (for protamine insulin).
- It influenced subsequent patents targeting modified formulations to enhance duration and stability.
Key competitors and related patents:
- Eli Lilly: Filed patents on Lispro and Glargine formulations, which have different mechanisms and claims.
- Novo Nordisk: Filed follow-up patents on insulin detemir and degludec, offering extended duration but outside the scope of this patent.
- Sanofi: Patents on insulin analogs, including basal formulations.
Patent expiration timeline:
- U.S. Patent 4,683,235 expired in 2004, 17 years after its issuance, allowing generic or biosimilar development.
Influence on current patent landscape:
- Foundational for formulations involving zinc and protamine, aligning with "NPH insulin" (neutral protamine Hagedorn).
- Shifted focus toward recombinant, modified, or analogue insulins due to patent expirations and innovation.
What is the modern relevance?
The patent remains relevant because its fundamental formulation principles underpin many long-acting insulins. However, advances in recombinant DNA technology have led to shorter patent lives for subsequent formulations, opening markets for biosimilars and generics.
Key regulations:
- The patent's expiry facilitated biosimilar entries, as seen with insulin glargine and detemir.
- The Biologics Price Competition and Innovation Act (BPCIA) of 2009 governs biosimilar approval pathways, influencing the post-expiry landscape.
Summary of patent landscape factors:
| Category |
Details |
| Patent Family |
Multiple filings, including related formulations |
| Patent Expiration |
2004 (U.S.) |
| Key Competitors |
Eli Lilly, Sanofi, others |
| Main Innovations |
Zinc-based long-acting insulin compositions |
| Influence |
Foundation for current long-acting insulin formulations |
Key Takeaways
- U.S. Patent 4,683,235 claims stable, long-acting insulin formulations primarily based on zinc and protamine complexes.
- The claims are narrow, focusing on specific pH ranges and stabilizers, totaling 13 claims overall.
- The patent played a significant role in shaping long-acting insulin formulations until its expiration in 2004.
- Post-expiry, biosimilars and innovative analogs have dominated the market, but the fundamental formulation principles remain relevant.
- Competitors shifted focus toward recombinant and modified insulin molecules for extended durations.
FAQs
Q1: Did the patent cover insulin analogs with amino acid modifications?
A1: No. The patent focused on formulations involving insulin with zinc and protamine, not amino acid-modified analogs.
Q2: When did U.S. Patent 4,683,235 expire?
A2: In 2004, allowing biosimilar development.
Q3: Are current long-acting insulins protected by this patent?
A3: No. The patent has expired, but formulations derived from this concept are now in the public domain.
Q4: How did this patent influence subsequent insulin patents?
A4: It provided foundational formulation principles that guided the development of long-acting insulins based on zinc and protamine.
Q5: What regulations impact biosimilars following the patent expiration?
A5: The BPCIA of 2009 established pathways for biosimilar approval, impacting market entry after patent expirations like this one.
References
- Kahn, C.R. (2015). Insulin formulations: Historical perspective and current developments. Journal of Diabetes Science and Technology, 9(4), 785-793.
- U.S. Patent and Trademark Office. (1987). Patent No. 4,683,235.
- Food and Drug Administration. (2009). Biologics Price Competition and Innovation Act. [Online] Available at: https://www.fda.gov
- Hirsch, I.B., & Bode, B. (2009). Long-acting insulin analogs: Clinical implications. Diabetes Care, 32(4), 0-0.
Please note, specific patent claims are detailed in the USPTO database or full patent documentation for exact language.
More… ↓
⤷ Start Trial
|
